These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30036933)

  • 21. AMCP Format dossier requests: manufacturer response and formulary implications for one large health plan.
    Spooner JJ; Gandhi PK; Connelly SB
    J Manag Care Pharm; 2007; 13(1):37-43. PubMed ID: 17269835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formularies in integrated health systems: Sharp HealthCare.
    Rizos AL; Levy E; Furnier J; Crowley K
    Am J Health Syst Pharm; 1996 Feb; 53(3):274-8. PubMed ID: 8808022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
    Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
    J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of an intervention in an academic Internal Medicine Clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change.
    Ramser KL; Sprabery LR; Hamann GL; George CM; Will A
    J Manag Care Pharm; 2009 May; 15(4):344-50. PubMed ID: 19422274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.
    Watkins JB; Minshall ME; Sullivan SD
    J Manag Care Pharm; 2006; 12(9):726-35. PubMed ID: 17249905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of pharmacoeconomics to formulary management in a health system setting.
    Studdert AL; Gong CL; Srinivas S; Chin AL; Deresinski S
    Am J Health Syst Pharm; 2019 Feb; 76(6):381-386. PubMed ID: 31361838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A survey of selective administration procedures in formulary maintenance.
    Quigley MA; Brown WM
    Hosp Pharm; 1981 Jul; 15(7):371-4, 378-80. PubMed ID: 10252001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The evolving use of cost-effectiveness analysis in formulary management within the Department of Veterans Affairs.
    Aspinall SL; Good CB; Glassman PA; Valentino MA
    Med Care; 2005 Jul; 43(7 Suppl):20-6. PubMed ID: 16056005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Developing Drug Reports for the Pharmacy and Therapeutics Committee.
    Longe RL; Riley MW
    Am J Hosp Pharm; 1976 Jul; 33(7):651-2. PubMed ID: 941920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmaceutical counseling: Between evidence-based medicine and profits.
    Egorova SN; Akhmetova T
    Int J Risk Saf Med; 2015; 27 Suppl 1():S87-8. PubMed ID: 26639727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternate financial incentives in multi-tiered formulary systems to improve accountability for outcomes.
    Chung RS; Taira DA; Noh C
    J Manag Care Pharm; 2003; 9(4):360-5. PubMed ID: 14613455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survey of formulary system policies and procedures.
    Rascati KL
    Am J Hosp Pharm; 1992 Jan; 49(1):100-3. PubMed ID: 1570847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Interview Series with Members of the ASHP Expert Panel on Formulary Management: Part 3: Sabrina W. Cole, PharmD.
    Ventola CL
    P T; 2010 Jan; 35(1):24-9. PubMed ID: 20182559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promoting interprofessional collaboration: pharmacy students teaching current and future prescribers about Medicare Part D.
    Lai CJ; Smith AR; Stebbins MR; Cutler TW; Lipton HL
    J Manag Care Pharm; 2011; 17(6):439-48. PubMed ID: 21787029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How to develop a proactive formulary system.
    Crane VS; Gonzalez ER; Hull BL
    Hosp Formul; 1994 Oct; 29(10):700-2, 704-8, 710. PubMed ID: 10137847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P & T Committee perspectives: maintaining a successful formulary system in a private community hospital.
    Benner EJ; Mykita L; Brown K
    Hosp Formul; 1990 Apr; 25(4):423-6, 428, 430. PubMed ID: 10104233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changing physician prescribing habits through a cost-effective first generation cephalosporin formulary.
    Cramer R; Wright C
    Hosp Pharm; 1989 Jan; 24(1):33-8. PubMed ID: 10312858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Formulary decisions for pre-1938 medications.
    Culley CM; Carroll BA; Skledar SJ
    Am J Health Syst Pharm; 2008 Jul; 65(14):1363-7. PubMed ID: 18593683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is P&T Ready to Add Rapid Cycle Analytics to Formulary?
    Altshuler D; Yu K; Papadopoulos J; Dabestani A
    Hosp Pharm; 2021 Oct; 56(5):430-435. PubMed ID: 34720142
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.